Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells $34,630.54 in Stock

Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Jennifer L. Good sold 5,263 shares of the company’s stock in a transaction that occurred on Friday, March 21st. The shares were sold at an average price of $6.58, for a total value of $34,630.54. Following the completion of the transaction, the chief executive officer now directly owns 213,313 shares of the company’s stock, valued at approximately $1,403,599.54. This trade represents a 2.41 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Trevi Therapeutics Stock Up 0.9 %

Shares of NASDAQ TRVI opened at $6.53 on Friday. Trevi Therapeutics, Inc. has a 12-month low of $2.30 and a 12-month high of $7.39. The firm’s 50-day simple moving average is $4.81 and its 200 day simple moving average is $3.85. The company has a market cap of $631.33 million, a price-to-earnings ratio of -14.84 and a beta of 0.90.

Trevi Therapeutics (NASDAQ:TRVI) last announced its earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. On average, equities analysts expect that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Analyst Ratings Changes

TRVI has been the topic of a number of research reports. Oppenheimer boosted their price objective on Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a research report on Tuesday, March 11th. HC Wainwright reissued a “buy” rating and issued a $12.50 price target on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Raymond James raised shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their price objective for the stock from $9.00 to $29.00 in a report on Monday, March 10th. D. Boral Capital reissued a “buy” rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Finally, B. Riley reissued a “buy” rating and issued a $20.00 target price (up from $11.00) on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Seven equities research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $17.56.

Institutional Investors Weigh In On Trevi Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Summit Investment Advisors Inc. lifted its holdings in Trevi Therapeutics by 84.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock worth $26,000 after acquiring an additional 2,894 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in Trevi Therapeutics by 130.9% during the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after purchasing an additional 6,764 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Trevi Therapeutics during the 4th quarter worth about $49,000. Squarepoint Ops LLC acquired a new position in shares of Trevi Therapeutics during the 4th quarter worth about $58,000. Finally, Two Sigma Advisers LP bought a new position in shares of Trevi Therapeutics in the 4th quarter valued at about $66,000. Institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.